EPO Reversal Overturns Copaxone 40mg Patent

Mylan Celebrates Invalidation Of European Dosing-Regimen Intellectual Property

 
• By Dave Wallace
  
EPA
The EPO has invalidated a dosing-regimen patent for Copaxone 40mg/ml • Source: Shutterstock

More from Legal & IP

More from Generics Bulletin